Latest Insulin glargine Stories
COPENHAGEN, September 30, 2010 /PRNewswire/ -- Zealand Pharma A/S, the biopharmaceutical company dedicated to the discovery and development of innovative peptide-based drugs, is pleased to note that its partner, sanofi-aventis, has today announced positive top-line results of the Phase III GETGOAL-L-ASIA trial which assessed the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist discovered by Zealand Pharma, in combination with basal insulin.
PARIS, Sept. 20 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today results of two studies presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting in Stockholm, Sweden.
PARIS, June 26 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today results of a study which demonstrated that patients using LantusÂ® (insulin glargine [rDNA origin] injection) once-daily and ApidraÂ® (insulin glulisine [rDNA origin] injection) before meals reported improved patient reported outcomes and decreased glycemic variability versus premix analog insulin.
PARIS, June 25 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that results from the RAndomized Study of Basal Bolus Insulin Therapy in the Inpatient Management of Patients with Type 2 Diabetes Undergoing General Surgery (RABBIT-2 Surgery) found that treatment with a basal-bolus regimen that included LantusÂ® (insulin glargine [rDNA origin] injection) once-daily and ApidraÂ® (insulin glulisine [rDNA origin] injection) before meals improved glycemic...
PARIS, April 29 /PRNewswire-FirstCall/ -- Change on Change at a constant reported exchange Q1 2010 Q1 2009 basis rates ------- ------- --------- --------- EUR EUR Net sales 7,385m 7,107m +3.9%...
JERSEY CITY, N.J., April 1 /PRNewswire/ -- Diabetes is a national epidemic. In the United States, a person is diagnosed with diabetes every 21 seconds.
SALEM, N.H., March 31 /PRNewswire/ -- AgaMatrix, Inc. and sanofi-aventis (EURONEXT: SAN and NYSE: SNY) today announced that they have signed a long-term agreement for the development, supply and commercialization of blood glucose monitoring (BGM) solutions.
The benefits of using insulin to treat diabetes far outweigh the risks, but a review just published online by IJCP, the International Journal of Clinical Practice, suggests that commonly used diabetes therapies may differ from each other when it comes to their influence on cancer risk.
WALTHAM, Mass., Dec. 3 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the type 2 diabetes drug market in Brazil will grow from $417 million in 2008 to $834 million in 2013.
NEW YORK, Nov.
- To swell, as grain or wood with water.